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be investigated by pooling RCT and RWE data in a response surface analysis. The 
maximum effect may be established in a region of treatment/dose combination 
not yet studied in a randomised setting. This methodology can also be used to 
determine which combination of patient’s characteristics will result in the most 
optimal effect for each (line) of therapy and as a result, provide targeted treatment 
for (groups of) patients based on their baseline characteristics. Further work could 
involve optimizing the response in higher dimensions.
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Objectives: To determine which clinical outcomes, both “soft” and “hard”, are cur-
rently used in phase III treatment studies for hematoncologic diseases, and what 
proportion of them use overall survival (OS) as the primary outcome. MethOds: 
Through a search in PubMed, we identified and analyzed all randomized clinical 
trials published in the last 10 years, for de novo treatments in adults. Results: 
The initial search yielded 310 references, from which 90 trials were selected. The 
most studied disease was multiple myeloma, with 29 studies, followed by non-
Hodgkin lymphoma with 26. The others were acute myeloid leukemia 12, chronic 
lymphocytic leukemia 10, chronic myeloid leukemia 8, myelodysplastic syndromes 
3 and Hodgkin lymphoma 2. The 90 studies had a total of 108 “primary” and 252 
“secondary” outcomes; 20 studies (22%) had OS as primary endpoint (though only 
3 of them reached statistical significance), in over 37 (41%) OS was grouped with 
other outcomes to form a composite endpoint. In 55 studies (61%) overall survival 
was a secondary outcome. Quality of life was a “secondary” outcome in 10 stud-
ies. cOnclusiOns: Although OS is the gold standard in cancer therapy, grouped 
outcomes, or others intermediate outcomes, such as progression-free survival or 
paraclinical indicators of disease activity are more frequently used and may be good 
predictors. Intermediate outcomes require smaller sample sizes and less follow-up. 
Their capacity to predict OS (or, indeed, quality of life) should be carefully assessed. 
Only in the most aggressive forms of cancer is routine use of OS survival justified 
as the primary endpoint.
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Objectives: The objectives of this study were: 1) to compare low back pain (LBP) 
patient valuations with those of the general population, 2) to explore how various 
aspects of health-related quality of life as measured by the EQ-5D-3L impact LBP 
patient valuations, and 3) to explore the implications of the choice of valuation 
method for cost-utility analyses (CUAs). MethOds: Data of 483 LBP patients who 
participated in a 52-week Dutch randomized controlled trial were used. Outcome 
measures included the EQ-5D-3L, EQ-VAS, and societal costs. Patient valuations were 
derived from the EQ-VAS. Population valuations were derived using a Dutch VAS-
based EQ-5D-3L value set. The difference and agreement between both valuations 
were assessed using t-tests and intraclass correlation coefficients (ICC), respectively. 
An ordinary least square linear regression model was constructed to explore how 
various aspects of health-related quality of life as measured by the ED-5D-3L impact 
LBP patient valuations. Moreover, two CUAs were performed; one using patient 
valuations and one using population valuations. Results: Patients valued their 
health state 0.098 (95%CI: 0.082 to 0.115) points higher compared with the general 
population. The two valuations had an ICC of 0.544. The regression model indicated 
that 22.2% of the variance in patient valuations was explained by the LBP patients’ 
EQ-5D-3L health state (R2= 0.222), and that LBP patients gave the most weight to 
the anxiety/depression dimension. In the CUA, the maximum probability of cost-
effectiveness was found to be lower when patient (i.e. 0.28) instead of population 
valuations (i.e. 0.38) were used. cOnclusiOns: This study demonstrated that LBP 
patients value their health state higher than members of the general population and 
that the choice of valuation method could have important implications for CUAs. As 
consensus does currently not exist regarding the question of ‘whose values count’, 
researchers are encouraged to explore these implications using sensitivity analyses.
PRM25
stOcHastIc MultIcRIteRIa accePtabIlIty analysIs In a bayesIan 
fRaMewORk
Wang J
Celgene International, Boudry, Switzerland
Objectives: Stochastic multicriteria acceptability analysis (SMAA) is a power-
ful tool for health technology benefit-risk assessment when health outcomes are 
assessed according to multicriteria and both the outcomes and preference weights 
are subject to uncertainty, in particular with missing weight information. We pro-
pose using a Bayesian approach for SMAA to provide an alternative or supplement 
to the standard SMAA. It can estimate the posterior distributions of decision maker’s 
preference weights on multicriteria, had he/she prefer treatment A over B. Given 
the preference on previous treatments and safety and efficacy profiles, it can also 
predict the decision maker’s preference on a new treatment. MethOds: The SMAA 
method was adapted to fit into the Bayesian framework, assuming that the weights 
follow a Dirichlet prior distribution. A simple Monte-Carlo procedure was developed 
to calculate the posterior distribution for the weights, and Bayesian estimates of 
major measures in standard SMAA were derived. An algorithm was also developed 
to predict future rankings. The method allows using informative, non-informative 
or hierarchical priors, and can be extended to other SMAA methods such as that 
based the prospect theory (SMAA-P). This method is applied to the assessment of 
in THIN from 2% to 13%. This work shows the potential for under-reporting of PSS 
in primary care data, and provides a method for improved identification of cases 
and control records for future studies.
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Objectives: The therapeutic options for Multiple Sclerosis(MS) improved over the 
past years with the approval of new substances. Therapeutic optimization must take 
into account an individualized assessment of clinical and imaging disease activity, 
treatment response as well as identifying early risk factors for treatment failure. 
This study will address by assess this issue by 1. Assess the utility of a tool that 
helps to identify patients with ongoing disease activity 2. The systematic collection 
of a broader set of functional domains to explore their potential to be used as a 
predictive measure of future disease activity or treatment response. 3. Evaluate the 
clinical course of patients according to NEDA-4 parameter as measured by relapse 
activity, disability progression, MRI activity and change in brain volume. 4. Assess 
the therapeutic effectiveness of switching to fingolimod if the patients are assessed 
to be failing their current first line therapy. MethOds: 1500 patients are planned to 
be included in this observational study. All patients with active disease as defined by 
Lublin et al., 2014, undergo a first evaluation of the patient status. Patients switching 
to fingolimod are followed for 3 years. The study set up and documentation param-
eters are based on three bullets: 1. Optimal patient management in daily clinical 
practice using the patient management system MSDS3D 2. State of the art evalua-
tion of the patient status using the MS-disease activity measurement tool 3. Multiple 
sclerosis optimized MRI-acquisition and analysis by central MRI-reading Results: 
and cOnclusiOns: PANGAEA 2.0 will give important insights on the predictive 
value of proposed treatment algorithms like the Lublin criteria and the modified Rio 
Score as well as the principle of NEDA (no evidence of disease activity) -4. It will also 
evaluate the benefit of a collection of a broad range of outcome parameter based on 
functional domains from a patient and physician perspective on therapy decisions.
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Objectives: Syntheses of time-to-event data often rely on published hazard 
ratios (HR) therefore assuming proportional hazards (PH). Methods now exist to 
reconstruct individual patient data (IPD) from published Kaplan-Meier (KM) plots. 
This enables the PH assumption to be formally tested, and a time ratio (TR) to 
be estimated as an alternative measure of relative treatment effect. While TRs do 
not require the PH assumption, these are rarely used in evidence synthesis. We 
compared TRs with HRs to demonstrate their ease of interpretation and transpar-
ency. MethOds: Relative treatment effect measures HRs and TRs were compared 
in terms of: scale, underlying assumptions, interpretation, availability in published 
literature and derivation. Results: HRs act on the log-hazard scale representing 
the ratio of hazards for treatment vs. control. TRs act on the log-failure time scale, 
representing the ratio of failure times for treatment vs. control. A HR< 1 represents 
a decrease in the event hazard whilst a TR< 1 represents an acceleration in time-
to-event, with treatment. The inverse of the TR, referred to as the acceleration fac-
tor (AF), therefore represents the same direction of benefit as for HRs. For TR= 2, 
AF= 0.5, the time-to-event for treatment is two times that for control. HRs are com-
monly reported to summarise the average relative treatment effect. TRs are rarely 
reported and hence less familiar to clinicians, but can be validated against any ratio 
of published survival times. cOnclusiOns: Relative treatment effects expressed 
as TRs are not commonly utilised in evidence synthesis due to unfamiliarity around 
interpretation and lack of availability in the published literature. When converted 
to AFs, TRs have a similar interpretation to HRs and can be estimated from IPD and 
published KM data. Therefore, evidence synthesis should no longer rely on published 
HRs as the measure of relative treatment effect when the PH assumption is violated.
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Objectives: Due to high costs, randomised clinical trials (RCTs) typically do not 
include a wide variety of doses and treatments within a single trial. Real-world 
evidence (RWE) can be used to fill the gaps left by treatment arms or doses not 
studied in first or second line RCTs. This is illustrated in rheumatoid arthritis (RA). 
The combined evidence can allow for investigating the area of dosing that can only 
be studied when all evidence is included. This may impact future dosing strategies 
that could result in approval of treatment (combinations) that may not have been 
studied otherwise but could substantially benefit patients with RA. MethOds: 
RCT and RWE data was combined in a network meta-analysis (NMA) to investigate 
treatment effects in patients with RA. Response surface methods were used to 
investigate the three dimensional surface of the observed effects as a function of 
doses for each pair of treatments. Optimization methods were used to establish the 
optimal treatment/dose region in patients with RA. Results: Results showed that 
including RWE has increased the totality of evidence with reduced uncertainty in 
first and second line treatment effects in patients with RA. The greatest evidence 
of effect was observed in a treatment/dose combination region not yet studied in 
RCTs cOnclusiOns: The optimal treatment regimen for patients with RA can 
